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Abstract
Background: Approximately 14 million persons living in areas endemic for lymphatic filariasis have lymphedema of the leg.
Clinical studies indicate that repeated episodes of bacterial acute dermatolymphangioadenitis (ADLA) lead to progression of
lymphedema and that basic lymphedema management, which emphasizes hygiene, skin care, exercise, and leg elevation,
can reduce ADLA frequency. However, few studies have prospectively evaluated the effectiveness of basic lymphedema
management or assessed the role of compressive bandaging for lymphedema in resource-poor settings.
Methodology/Principal Findings: Between 1995 and 1998, we prospectively monitored ADLA incidence and leg volume in
175 persons with lymphedema of the leg who enrolled in a lymphedema clinic in Leogane, Haiti, an area endemic for
Wuchereria bancrofti. During the first phase of the study, when a major focus of the program was to reduce leg volume
using compression bandages, ADLA incidence was 1.56 episodes per person-year. After March 1997, when hygiene and skin
care were systematically emphasized and bandaging discouraged, ADLA incidence decreased to 0.48 episodes per person-
year (P,0.0001). ADLA incidence was significantly associated with leg volume, stage of lymphedema, illiteracy, and use of
compression bandages. Leg volume decreased in 78% of patients; over the entire study period, this reduction was
statistically significant only for legs with stage 2 lymphedema (P = 0.01).
Conclusions/Significance: Basic lymphedema management, which emphasized hygiene and self-care, was associated with
a 69% reduction in ADLA incidence. Use of compression bandages in this setting was associated with an increased risk of
ADLA. Basic lymphedema management is feasible and effective in resource-limited areas that are endemic for lymphatic
filariasis.
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Introduction
Lymphedema of the leg and its advanced form, known as
elephantiasis, are major causes of disability and morbidity in
filariasis-endemic areas, with an estimated 14 million cases
worldwide [1]. When the World Health Organization’s Global
Program to Eliminate Lymphatic Filariasis (GPELF) was launched
in 1998, its stated goals included not only interrupting transmis-
sion of the parasite, but also providing care to persons who suffer
from clinical disease [2,3]. During the 1990s, several studies in
filariasis-endemic areas highlighted the importance of repeated
episodes of acute bacterial dermatolymphangioadenitis (ADLA) in
the progression of lymphedema severity [4–8]. These inflamma-
tory episodes, characterized by intense pain, swelling, fever, and
chills, accelerate damage to the peripheral lymphatic channels in
the skin, which leads to worsened lymphatic dysfunction, fibrosis,
and increased risk of further ADLA episodes. Clinical studies
suggest that basic lymphedema management – including hygiene,
skin care, elevation of the limb, and range-of-motion exercises –
can halt, or perhaps even partially reverse, this progression [9–14].
The current prospective study was done to test, under field
conditions, the feasibility and effectiveness of basic lymphedema
management as a public health intervention in a resource-poor
setting.
Leogane, Haiti, located approximately 30 km west of Port au
Prince, has long been endemic for lymphatic filariasis; the
prevalence of Wuchereria bancrofti microfilaremia was 16% in
2000 [15]. The outpatient clinic at Ste. Croix Hospital, the major
health facility for Leogane Commune, was the site of this study.
Lymphedema of the leg, which disproportionately affects women
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[16], is a major public health problem in Leogane [17]. As in
many other areas where bancroftian filariasis is endemic, few
persons with lymphedema of the leg remain infected with the
parasite [18].
Methods
The study was approved by the Ethics Committee of Ste. Croix
Hospital and by the Institutional Review Board of the Centers for
Disease Control and Prevention. Patients were included in the
study if they had lymphedema of the leg, agreed to return to the
hospital clinic for follow-up evaluations, had no obvious cause of
edema such as tumor or congenital anomalies, and provided
written informed consent. On their initial visit to the clinic, the
volume of each leg was measured using a water displacement
method, and each leg was classified as to stage of lymphedema
using the 7-stage system of Dreyer and colleagues [19]. In this
system, stage 1 is characterized by minimal swelling that reverses
with horizontal rest. Stage 2 lymphedema does not completely
reverse, but the skin appears normal. In stage 3 lymphedema the
skin is thickened so that shallow skin folds are apparent. For
purposes of analysis, we combined the Dreyer stages 4–7 into a
single fourth-stage category; briefly, these are characterized by
protrusions or ‘‘knobs’’ on the skin (stage 4), deep skin folds (stage
5), mossy lesions (stage 6) and severity that inhibits performing
daily activities (stage 7) [19]. Lymphedema was considered
bilateral if both legs had lymphedema of stage 2 or greater.
Information was collected on patient age, gender, literacy,
education, duration of lymphedema, and number of ADLA
episodes recalled by the patient during the previous 12 months.
Patients were instructed how to wash their legs, apply antifungal
and antibiotic creams or disinfectant (KMnO4) to the skin when
indicated, elevate the foot of the bed, and perform range-of-
motion exercises. They were asked to return to the hospital clinic
every 4–6 weeks for routine follow-up, at which time information
was collected on any ADLA episodes since the previous visit that
had not been observed by clinic staff, as well as compliance with
the components of basic lymphedema management. Compliance
was assessed by asking each patient a standardized list of questions
regarding the frequency of washing the leg, performing leg
exercises, elevating the leg during the day, and sleeping with the
foot of the bed raised since the previous visit. Frequency categories
included ‘‘every day,’’ ‘‘most days,’’ ‘‘occasionally,’’ or ‘‘not at all.’’
Leg volume was again measured and patients were instructed and
encouraged to continue practicing lymphedema management
measures.
Patients also were told to return to the clinic if they developed
signs of ADLA, where they were evaluated and given care, which
included antibiotics, and, if necessary, hospitalized. This care was
provided free of charge. Most patients provided their own supplies
for washing the legs and feet, including soap, basins, and towels;
these were provided free of charge to the few patients who did not
already have and could not afford them. Antiseptic and topical
antimicrobial agents for skin lesions were provided by the clinic
free of charge to all patients. Other than free care and supplies,
patients received no financial incentives to participate. Home visits
were made on an ad-hoc basis to assess patient capacity for self-
care and to encourage patient compliance. An effort also was
made to conduct home visits when patients missed one or more
regularly-scheduled clinic appointments. Data were not systemat-
ically recorded during these home visits.
Pilot phase
In June 1995, the physical therapist at Ste. Croix (JLC) recruited
a group of 30 patients with lymphedema of the leg to participate in
a pilot project of basic lymphedema management. The goals of
this pilot were to assess the feasibility and acceptance of basic
lymphedema management in a small group of patients and to test
the feasibility of volumetric measurement in this setting. During
this pilot phase, leg volume sometimes was measured twice a day
to assess diurnal variation (data not shown). The pilot was
intended to last two months, but it continued with these 30
patients until the spring of 1996, when increased funding allowed
the project to scale up. For the purposes of analysis, the pilot study
is considered as part of Phase I.
Phase I
With the project expansion in March 1996, eight additional
staff, including a nurse, a community health worker, and others
with high school-level education but no health background were
trained as lymphedema technicians. A hospital physician (FL)
provided consultation and medical care as needed. During Phase
I, an attempt was made to compare the effectiveness of basic
lymphedema management with a more intensive method that
included compressive bandaging, a component of ‘‘complex
decongestive physiotherapy’’ [20]. Two to four weeks of
compressive bandaging (using ComprilanH) resulted in rapid
volume reduction, which was maintained with a locally designed
and produced compressive garment made of VelcroH. However,
because it resulted in rapid volume reduction, the popularity of
compressive bandaging made it impossible to randomize patients
to the non-bandage intervention group.
Phase II
In March 1997, Dr. Gerusa Dreyer, who had developed a basic
lymphedema management program in Recife, Brazil, visited
Leogane to review the project and to conduct training for the staff.
As a result of that visit, the program shifted its primary focus from
reducing leg volume to preventing ADLA through hygiene and
skin care. Use of compressive bandaging and garments was
no longer encouraged and their use declined dramatically. In
Author Summary
Lymphatic filariasis is a parasitic disease that is spread by
mosquitoes. In tropical countries where lymphatic filariasis
occurs, approximately 14 million people suffer from
chronic swelling of the leg, known as lymphedema.
Repeated episodes of bacterial skin infection (acute
attacks) cause lymphedema to progress to its disfiguring
form, elephantiasis. To help achieve the goal of eliminating
lymphatic filariasis globally, the World Health Organization
recommends basic lymphedema management, which
emphasizes hygiene, skin care, exercise, and leg elevation.
Its effectiveness in reducing acute attack frequency, as well
as the role of compressive bandaging, have not been
adequately evaluated in filariasis-endemic areas. Between
1995 and 1998, we studied 175 people with lymphedema
of the leg in Leogane, Haiti. During Phase I of the study,
when compression bandaging was used to reduce leg
volume, the average acute attack rate was 1.56 episodes
per year; it was greater in people who were illiterate and
those who used compression bandages. After March 1997,
when hygiene and skin care were emphasized and
bandaging discouraged, acute attack frequency signifi-
cantly decreased to 0.48 episodes per year. This study
highlights the effectiveness of hygiene and skin care, as
well as limitations of compressive bandaging, in managing
lymphedema in filariasis-endemic areas.
Lymphedema Management in Lymphatic Filariasis
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November 1997, a colorful booklet with the messages of basic
lymphedema management was given to each patient, and a ‘‘soap
opera’’ was broadcast over local radio that depicted the life of a
young woman with lymphedema and how she benefited from
lymphedema self-care.
Statistical analysis
The analysis was limited to patients who returned to the clinic
for at least 5 routinely scheduled visits over a period of least 6
months. We considered shorter periods of observation inadequate
to evaluate the effect of the intervention. ADLA incidence was
calculated as episodes per person-year of observation. Changes in
leg volume were calculated by subtracting last-measured volume
from initial volume during a specified time period. The pooled t-
test was used to compare differences in age by study phase; the
paired t-test to compare changes in leg volumes; the chi-square or
Fisher’s Exact test to compare proportions associated with gender
and literacy; and Poisson regression to calculate and compare
ADLA incidence rates and to identify factors associated with
ADLA episodes. The effect of factors associated with leg volume
was investigated using multivariate regression. All regressions were
run using SAS PROC GENMOD, using the generalized estimating
equations (GEE) procedure to adjust for correlation of multiple
observations (e.g., ADLA episodes in different legs) from the same
individual over time [21]. Analyses were performed using SAS
version 9.2, SAS Institute Inc, Cary, NC, USA. Statistical
significance was set at alpha= 0.05.
Results
A total of 302 patients first received lymphedema care at the
Ste. Croix Hospital clinic between June 1995 and December 1997.
They came from filariasis-endemic areas throughout the country.
Clinic resources were sufficient during this time to enroll 230
patients who met the inclusion criteria. Of these, 175 (76%)
returned to the clinic for at least 5 routinely scheduled visits over a
period of least 6 months. A total of 145 (82.9%) of these patients
were female and the mean age was 37.3 years (range, 10–85).
Eighty-four percent lived within Leogane Commune. Eighty-seven
(49.7%) patients reported they could read and write.
Reported duration of edema at the time of entry into the study
was 11.3 years (range, ,1 to 50) (Table 1). Using the 4-stage
classification of lymphedema, 78 (44.6%) patients had skin changes
characteristic of stage 3 and 12 (6.9%) had frank elephantiasis,
stage 4. Lymphedema stage was not significantly associated with
gender (P= 0.76). Fifty-five (31.4%) patients had bilateral
lymphedema ($stage 2). Mean volume of affected legs on entry
into the study ranged from 1586 mL for unaffected legs to
3422 mL for stage 4. Volume increased significantly with
lymphedema stage (P,0.001), although considerable variation
was observed within each stage.
The 175 patients were observed for a total of 3874 months, for a
mean of 22.1 months (range, 6.3–41.2). The number of routine
clinic visits ranged from 5 to 123 (mean, 26.9). In all, 127 patients
entered the study during Phase I (July 1995–March 1997) and an
additional 48 entered during Phase II (after April 1, 1997). These
two groups did not differ significantly by age, sex, literacy, or
lymphedema stage or duration, but patients who entered in Phase
II reported having had significantly fewer ADLA episodes during
the 12 months before entering the study (Table 1). All patients
continued through the end of the study in December 1998.
ADLA
During the 12 months before entering the program, the 175
patients reported a mean of 2.1 episodes of ADLA (range 0–13),
with a mean duration of 2.6 days each (range ,1 day–44 days).
Reported ADLA incidence by 12-month recall was not associated
with patient age or sex but was significantly associated with
illiteracy (RR 1.6, P= 0.01), bilateral lymphedema (RR 1.6,
P= 0.02) and greater lymphedema stage (0.67, 1.72, 2.32, and
3.08 episodes per year for persons with stages 1 through 4,
respectively, P= 0.01).
During the study, a total of 242 ADLA episodes were reported,
for an overall incidence of 0.75 episodes per person-year, with a
range of 0 to 10 per patient. Of these episodes, 141 (58%) were
witnessed by clinic staff. Mean reported duration of each ADLA
Table 1. Characteristics of 175 patients with lymphedema who participated in the study, including 127 persons who entered
before April 1, 1997 (during Phase I) and 48 who entered after April 1, 1997 (Phase II), univariate analysis.
Characteristic All patients
Entered in Phase I
(before April 1997)
Entered in Phase II
(after April 1, 1997) P*
No. persons 175 127 48
Mean age in years (range) 37.3 (10–85) 36.6 (10–85) 39.2 (12–75) 0.34
No. (%) female 145 (82.9%) 108 (85.0%) 37 (77.1%) 0.26
No. (%) literate 87 (49.7%) 58 (45.7%) 29 (60.4%) 0.09
Mean (range) duration of lymphedema upon entry into study (years) 11.3 (,1–50) 10.5 (,1–50) 13.3 (,1–38) 0.10
Mean no. of reported ADLA episodes in the year before entering the study (range) 2.1 (0–13) 2.4 (0–13) 1.3 (0–6) 0.0004
No. legs 350 254 96
Lymphedema stage
0 (no edema) 85 (24.3) 59 (23.2) 26 (27.1) 0.1467
1 38 (10.8) 29 (11.4) 9 (9.4)
2 129 (36.9) 88 (34.7) 41 (42.7)
3 85 (24.3) 70 (27.6) 15 (15.6)
4 13 (3.7) 8 (3.1) 5 (5.2)
* Comparing 127 persons entering the study in Phase I with the 48 who entered in Phase II.
doi:10.1371/journal.pntd.0000668.t001
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episode was 3.9 days (range 1–22). Eighty-seven patients (49.7%)
had no ADLA during the study, 67 (38.3%) had an annual
incidence of ,2.0 per person-year, and 21 (12.0%) experienced
two or more episodes per year. In univariate analysis, ADLA
incidence during the study was positively associated with
lymphedema stage and leg volume, illiteracy, use of compression
bandages or garments, and reported frequency of ADLA before
entering the study (Table 2). No consistent seasonal pattern was
observed for ADLA incidence, although it tended to increase
between the third and fourth quarters of the year; this increase was
statistically significant (P = 0.006) only for 1997.
Because the emphasis of the program shifted from leg volume
reduction during Phase I to ADLA prevention through self-care
during Phase II, we compared ADLA incidence for these two
periods (Figure 1). In Phase I, the incidence of ADLA was 1.56
episodes per person-year, compared to 0.48 overall in Phase II
(P,0.0001). A significant reduction was observed even when the
analysis was restricted to those who entered the study during Phase
I. Among these 127 persons, ADLA incidence decreased to 0.54
per person-year during Phase II (P,0.0001). ADLA incidence
during Phase II was even lower for the 48 persons who entered the
study during Phase II, 0.22 episodes per person-year (P,0.0001)
(Table 3).
A multivariate Poisson regression analysis considered the effect
of treatment compliance, illiteracy, gender, and use of compres-
sion bandages on ADLA incidence among the 127 persons who
entered the study during Phase I, when compressive bandaging use
was most common. Only illiteracy and use of compression
bandages or garments were significantly associated with ADLA
incidence. A significant (P = 0.02) interactive effect of bandaging
and illiteracy was observed. Among illiterate persons, mean ADLA
incidence did not change with or without use of compression
bandages (1.1 episodes per year vs. 1.0 episode per year,
respectively). However, among literate persons, those who ever
used compression bandages had an overall ADLA incidence of
0.76 per year, compared to 0.20 per year for those who never used
compression bandages or garments (P = 0.005).
Leg volume
Of 175 patients, 137 (78.3%) experienced some reduction in leg
volume during the study; volume decreased in 66.4% of
lymphedematous legs (median reduction, 90 ml). In general,
volume decreased dramatically following application of compres-
sive bandages and increased rapidly during ADLA. Compared to
leg volume on entering the study, mean leg volume at the end of
the study was 14 mL greater in normal legs and 5 mL greater in
legs with stage 1 lymphedema. Mean decreases of 59 mL, 93 mL,
and 571 mL were observed for lymphedema stages 2, 3, and 4,
respectively, statistically significant over the entire study period
only for stage 2 (P= 0.01) (Table 4). Controlling for study phase,
volume reduction in all 175 patients was significantly associated
with increasing lymphedema stage (P= 0.005), lower frequency of
ADLA during the study period (P= 0.016), and use of compressive
bandages (a mean decrease of 86.6 mL, compared to 8.2 mL in
Table 2. Incidence of acute dermatolymphangioadenitis (ADLA), in episodes per person-year, among 175 patients with
lymphedema in Leogane, Haiti, by demographic, disease-related, and treatment-related factors, univariate analysis.
Characteristic Value or status N ADLA incidence (range) P
Gender Male 30 .83 (0–5.6) .4946
Female 145 .74 (0–2.9)
Age (years) $40 80 .77 (0–5.6) .8093
,40 90 .75 (0–3.2)
Literacy Illiterate 88 1.01 (0–5.6) ,.0001
Literate 87 .47 (0–2.5)
Bilateral lymphedema (.stage 2 bilaterally) Yes 55 .87 (0–3.0) .0740
No 120 .69 (0–5.6)
Lymphedema duration (years) $10 78 .72 (0–3.8) .6275
,10 97 .77 (0–5.6)
Median leg volume (n = 350 legs) $2000 mL 125 1.35 ,.0001
1700–1999 mL 117 .52 .13
,1700 mL 108 .33 Referent
ADLA frequency during the year before entering the study, based
on 12-month recall (episodes per year)
.2.0 84 .94 (0–5.6) .0004
0.1–2.0 55 .59 (0–3.8) .2416
0 36 .44 (0–2.9) Referent
Ever used compression bandages or garments during study Yes 122 .88 ,.0001
No 53 .43 Referent
Lymphedema stage, by leg (n = 350 legs) 4 13 1.08 ,.0001
3 85 1.52 ,.0001
2 129 .76 ,.0001
1 38 .37 .0015
0 85 0 Referent
doi:10.1371/journal.pntd.0000668.t002
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Figure 1. Quarterly incidence of acute dermatolymphangioadenitis (ADLA) in 175 lymphedema patients, 1995–1988, Leogane,
Haiti. Arrow indicates the point at which the program focus shifted away from decreasing leg volume using compression bandages to reducing the
frequency of ADLA through hygiene, skin care, range-of-motion exercises and leg elevation.
doi:10.1371/journal.pntd.0000668.g001
Table 3. Acute dermatolymphangioadenitis (ADLA) among the 127 lymphedema patients who entered the study during Phase I
(before April 1, 1997); for the 48 who entered the study during Phase II (after April 1, 1997); and for all 175 participants combined,
univariate analysis.
Characteristic
Patients Who Entered the Study During Phase
I (N=127)
Patients Who Entered
the Study During Phase
II (N=48) All Participants (N=175)
Period of Observation
Year before
Study* Phase I Phase II
Phases
I & II
Year before
Study* Phase II
Year before
Study*
Phases
I & II
No. person-years of follow-up 127 81.6 191.8 273.4 48 49.3 175 322.8
No. ADLA episodes 298 127 104 231 63 11 361 242
ADLA incidence** 2.35 1.56{ 0.54{{ 0.84 1.31 0.22{ 2.06 0.75
No. (%) persons with ADLA incidence of:
0 24 (18.9%) 71 (55.9%) 68 (53.5%) 47 (37.0%) 12 (25.0%) 40 (83.3%) 36 (20.6%) 87 (49.7%)
0.1–1.99 per year 35 (27.6%) 21 (16.5%) 47 (37.0%) 61 (48.0%) 20 (41.7%) 6 (12.5%) 55 (31.4%) 67 (38.3%)
$2.00 per year 68 (53.5%) 35 (27.6%) 12 (9.5%) 19 (15.0%) 16 (33.3%) 2 (4.2%) 84 (48.0%) 21 (12.0%)
ADLA incidence**
Any use of compression bandage or garment – 1.76 0.52 0.97 – 0.25 – .88
No use of compression bandage or garment – 1.00 0.57 0.50 – 0.19 – .43
P value" ,.0001 0.51 .0002 .68 .0001
* Based on 1-year recall.
** ADLA episodes per person-year.
{ P,0.0001, ADLA incidence in Phase I vs. Phase II for persons participating during both phases.
{ P,0.0001, ADLA incidence in Phase II, comparing persons who entered during Phase I and those who entered in Phase II.
" Comparing ADLA incidence for persons who used compression bandages or garments and those who did not.
doi:10.1371/journal.pntd.0000668.t003
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lymphedematous legs in which no compression was used,
P = 0.039), but not with age or sex.
Reported compliance
For the purposes of data analysis, compliance with the four
recommended practices of leg washing, exercises, leg elevation,
and sleeping with the foot of the bed raised was defined as having
reported, on at least 75% of all clinic visits, that the behaviors had
been practiced every day since the previous clinic visit. Using this
definition, compliance rates were 88.0%, 38.3%, 69.7%, and
49.7% for these four practices, respectively. Significant increases in
daily compliance between Phase I and Phase II were observed for
leg washing (from 61.7% to 94.3%, P,0.001), leg elevation
(59.2% to 68.6%, P= 0.01), and sleeping with the foot of the bed
elevated (40.8% to 51.4%, P,0.001). Overall compliance was
calculated by summing the percentage figures for all four
recommended practices; a score of $300 (of a possible 400) was
considered compliant. Overall compliance increased from 45.8%
to 66.3% between Phase I and Phase II (P = 0.003). In a
multivariate Poisson regression analysis, compliance was signifi-
cantly associated with female gender (OR 1.6, 95% Confidence
Interval [CI] 1.0–2.5, P= 0.05) and age .40 years (OR 1.5, 95%
CI 1.1–2.0, P= 0.02), but not with literacy or lymphedema stage.
Discussion
This prospective study provides evidence that basic lymphede-
ma management is feasible and acceptable to patients in resource-
poor areas where lymphatic filariasis is endemic. In general,
patients were able to incorporate basic self-care measures,
especially leg washing, into their daily routines. When proper
hygiene and skin care were emphasized, the incidence of ADLA
decreased rapidly to 31% of earlier levels and these reductions
were sustained over time. A follow-up study by Dahl and
colleagues in 2000–2001 showed that ADLA incidence in these
patients remained low and even decreased further (Dahl, BA,
unpublished thesis, Emory University, Atlanta, Georgia).
Recent studies indicate that, in addition to being a critical risk
factor for progression of lymphedema [4–8,13,14], ADLA epi-
sodes are strongly associated with poor quality of life [10,22–28].
Thus, reducing ADLA frequency is arguably the most important
objective of lymphedema management in resource-poor countries.
Accordingly, ADLA has emerged as a key indicator for monitoring
lymphedema management programs in filariasis-endemic areas
[29].
In contrast, the usefulness of leg volume as an indicator of
clinical improvement in filariasis-endemic areas seems limited. Leg
volume, albeit an ‘‘objective’’ measure, varied widely with use of
compression garments and, to an extent, with time of day (data not
shown). Overall, leg volume decreased in 78% of our patients, but
these reductions were generally modest, and statistically significant
only for stage 2 lymphedema. Our initial focus on reducing leg
volume, although popular with patients, distracted attention from
hygiene and skin care; as a result, no significant reduction in
ADLA incidence was observed during Phase I of the study.
Compression bandages reduced leg volume quickly, but their use
was associated with an increase in ADLA incidence. It was difficult
to keep the compression bandages clean, and they were
prohibitively expensive – equivalent to the annual income of
many patients. Frequent visits to the clinic for reapplication of
compression bandages in the initial stages of treatment also
fostered dependence on clinic staff and undermined key messages
of self-reliance and self-care. Thus, although reduction in leg
volume is a desirable outcome, our experience suggests that it
should not be the primary goal of lymphedema treatment in
resource-poor settings.
After receiving training from Dr. Dreyer midway through the
study, the clinic staff was better equipped to deliver simple, clear,
assertive messages to patients regarding hygiene and skin care.
These messages were later reinforced by a simple booklet that was
given to each patient, opportunities to participate in support
groups, and a radio drama about a young woman with
lymphedema that was aired repeatedly on local radio. With these
interventions, ADLA incidence dropped dramatically and re-
Table 4. Mean leg volume, in mL, among lymphedema patients in Leogane, Haiti, a) upon study entry, b) at the beginning of
Phase II, and c) at the end of the study, by lymphedema stage and phase during which the patient entered the study.
Stage Entered study during Phase I (N=127 persons, 254 legs)
Entered study during Phase II (N=48
persons, 96 legs)
All participants (N=175 persons,
350 legs)
No.
legs
Mean pre-
treatment leg
volume at
beginning of
Phase I (range)
Mean leg volume
at end of Phase I
(beginning of
Phase II) (range)
Mean leg
volume at
end of Phase
II (range)
No.
legs
Mean pre-
treatment leg
volume at the
beginning of
Phase II (range)
Mean leg
volume at
end of Phase
II (range)
No.
legs
Mean leg
volume on
entry into the
study (range)*
Mean leg volume
on last date of
participation in
the study
0 59 1573 (1110–2445) 1592 (1195–2460) 1598 (1145–
2360)
26 1610 (1080–2160) 1604 (1310–
2130)
85 1586 (1080–2445) 1600 (1145–2360)
1 29 1664 (1205–2155) 17141 (1360–2215) 1718 (1250–
2285)
9 1937 (1515–2760) 1786 (1470–
2030)
38 1729 (1205–2760) 1734 (1250–2285)
2 88 1994 (1020–3220) 19531 (1460–2890) 19471 (1260–
2945)
41 1986 (1450–2835) 19092 (1230–
2970)
129 1991 (1020–3220) 19351 (1230–2970)
3 70 2328 (1225–4540) 2293 (1645–3720) 2317 (1645–
3910)
15 2839 (1920–3700) 23542 (1850–
3260)
85 2417 (1225–4540) 2324 (1645–3910)
4 8 3284 (2515–4595) 29031 (2135–3750) 27061 (1820–
3500)
5 3644 (2390–4760) 3082 (1510–
4010)
13 3422 (2390–4760) 28513 (1510–4010)
1Statistically significant (P = 0.01) difference compared to mean leg volume at entry into the study.
2Statistically significant (P,0.05) difference compared to mean leg volume at the beginning of Phase II.
3P = 0.05, compared to mean leg volume at entry into study.
* Regardless of which phase the patient entered the study.
doi:10.1371/journal.pntd.0000668.t004
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mained low. The relative contribution of each component of the
overall intervention is unclear; we believe that they acted
synergistically. Coreil and colleagues showed that patients in
Leogane who regularly participated in support groups had a lower
incidence of ADLA than those who did not [30]. In addition, self-
efficacy (belief in one’s ability to perform lymphedema self-care)
increased significantly following distribution of booklets and
broadcasts of the radio dramas (Wendt, JM, unpublished thesis,
Emory University, Atlanta, GA).
The number and duration of patient contacts required for
patients to understand, become proficient in, and fully committed
to life-long lymphedema self-care is not clear. In practice, the
intensity of patient training and follow-up varies among filariasis
programs [29]. Our results indicate that patients who were
illiterate and those with advanced disease continued to be at risk of
ADLA episodes. These results suggest that more intensive effort
may be needed for such patients, such as home visits and support
groups. The fact that illiterate persons remained at a 2-fold risk of
ADLA throughout the study, even when controlling for other
factors, also suggests that illiteracy may be a marker for other
factors related to ADLA incidence, such as lower self-efficacy or
increased risk of skin lesions that predispose to ADLA [31,32].
In addition to reduced ADLA incidence, we observed other
improvements in quality of life among patients in this study. These
were often dramatic. Patients commonly reported decreased
stigma and shame and a return to active life, including school or
work [30, Wendt JM, unpublished]. Those with advanced
lymphedema and multiple skin folds and lesions reported, often
for the first time in years, the elimination of offensive odor. Serial
biopsies in a subset of patients confirmed a decrease in chronic
inflammation in lymphedematous legs [33].
Despite these remarkable changes at the tissue level, most
patients did not experience reduction in lymphedema stage. The
4-stage classification that we used is not particularly sensitive to
localized changes, and considerable heterogeneity can be found
within each stage. Most of the lymphedema classification and
staging systems that have been proposed suffer from these
limitations [34].
Studies have reported that the incidence of adenolymphangitis
(presumably ADLA or ADLA-like) may decrease following mass
treatment with antifilarial drugs [35–38]. The current study was
completed almost two years before mass treatment was initiated in
Leogane [15]; diethylcarbamazine was not readily available.
Therefore, it seems unlikely that the clinical improvement and
decreased ADLA frequency that we observed can be attributed to
reduced transmission of W. bancrofti.
Seasonal fluctuations in ADLA, associated with rainfall, have
been reported in other studies [39]. We observed no consistent
seasonal trends in ADLA incidence. The tendency for ADLA
incidence to increase between the third and fourth quarters was
statistically significant only for 1997. The reason for this is not
clear. Rainfall patterns varied from year to year in Haiti during the
study period, and the fall of 1997 was relatively dry.
Prospective ADLA monitoring, as was done in this study, is
accurate, but expensive. The accuracy of patient recall over longer
periods is unknown, but the pain and suffering associated with
ADLA make it a memorable event. Among the 127 patients who
entered the study during Phase I, the observed incidence of ADLA
during Phase I was 1.6 episodes per person-year, compared to 2.4
self-reported for the 12 months before entering the study. It is risky
to compare retrospective and prospective data, and it also is possible
that messages regarding hygiene and skin care during Phase I, albeit
sub-optimal, might have reduced ADLA incidence from baseline
levels. However, the data suggest that 12-month recall may be
adequate for rapid epidemiologic assessments or program moni-
toring. Additional research is warranted to assess reliability of 12-
month ADLA recall in different filariasis-endemic areas.
The preponderance of women in our study sample reflects the
gender distribution among persons with lymphedema in the
Leogane population [16]. In many areas where bancroftian
filariasis is endemic, lymphedema of the leg is more common in
women than in men, although this finding is not universal [38].
This study has several limitations. First, both the incidence of
ADLA and compliance with lymphedema self-care were assessed
by self-report – a method that, typically, is less than completely
reliable. Recall of ADLA episodes during the year before entering
the study was facilitated by careful questioning and using
memorable public events to help ‘‘frame’’ the previous 12 months.
During the study, patients were encouraged to report ADLA and
compliance accurately and honestly, and they were assured that
clinical care would continue, free of charge, regardless of what they
reported. Some 58% of ADLA episodes reported by patients were
observed and confirmed by research staff at the clinic. In many of
the remaining cases, patients were seen within 1–2 weeks after the
episode, when clinical signs (such as peeling of the skin, warmth,
or edema [19]) were still visible. Skin condition and interdigital
lesions were carefully assessed during routine clinic visits, and
they provided a check on self-reported compliance. Ad-hoc home
visits also encouraged accurate self-reporting. For example, the
absence of soap, a clean towel, or an appropriate washing basin
would call into question high levels of self-reported compliance.
Second, because of ethical concerns about withholding
treatment, we did not collect comparative prospective data on a
control group of patients. Further, although we desired to
randomize patients with regard to compressive bandaging, we
were unable to do so. However, we were able to compare ADLA
incidence as a function of the focus of our programmatic
intervention (i.e., leg volume during Phase I and ADLA incidence
during Phase II).
Third, because of the conditions under which this study was
conducted, it cannot be regarded as a study of the efficacy of
lymphedema management. We had limited on-site access to
specialists in lymphedema management, our staff was comprised
mostly of motivated young people rather than health professionals,
and the intervention evolved as we gained experience. It is likely
that even greater reductions in ADLA frequency would be
observed under more optimal conditions.
Despite these limitations, our results suggest that basic
lymphedema management is both feasible and effective in
filariasis-endemic areas where resources are limited. When
provided with the skills and motivation to practice lymphedema
self-care, most patients will do so. However, simple messages that
unequivocally emphasize the importance of hygiene and skin care
are important. Our experience also suggests that compressive
bandages, although useful for individual patients, should not be
the mainstay of treatment in filariasis-endemic areas, and that
volume reduction may not be the optimal measure of success.
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